nav-left cat-right
cat-right

XenoPort and GSK End Horizant Collaboration

XenoPort has reached an agreement with Glaxo Group (GSK) to terminate their collaboration agreement concerning Horizant® (gabapentin enacarbil) extended-release tablets, for which GSK held commercialization rights and certain development rights in the United States. GSK is returning Horizant rights to XenoPort and providing certain assistance during a transition period. The termination and transition agreement also...

Immune Pharmaceuticals Merges with EpiCept

Immune Pharmaceuticals and EpiCept have agreed to merge. The combined company, to be named Immune Pharmaceuticals, will be primarily focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. Immune Pharmaceuticals is an Israel- and U.S.-based biopharmaceutical company focused on the development of next-generation antibody therapeutics addressing unmet...

BioCryst Halts Enrollment in Phase III Peramivir T...

BioCryst said today it halted patient enrollment in a Phase III trial of its flu drug candidate peramivir. In a statement, the company cited an interim analysis by its data monitoring committee that found just a small difference between peramivir and control groups for the primary endpoint, changes to vital signs and oxygen saturation through the 10th day. The company also cited the recalculation of its sample size,...

Validating Assays to Guide Personalized Therapy

med fusion and Theranostics Health are planning to work together to validate the clinical utility of the latter’s TheraLink™ Assays for use as molecular diagnostic aids in therapeutic decision making. The assays are based on measuring the activation status of signal transduction pathways involved in the development and growth of human cancers, to provide oncologists with a molecular map of each tumor’s molecular...

Blocking an Enzyme Boosts Chemotherapy Potency

Partially blocking an oxygen-sensing enzyme known as prolyl hydroxylase domain protein 2 (PHD2) could increase the effectiveness of chemotherapy and help reduce the toxic side effects of treatment on normal tissues, researchers report. PHD2 is an oxygen/redox-sensitive enzyme that induces cellular adaptations to stress conditions. Previous work on tumors by a team at the Vesalius Research Center at the Flanders...

Gene Tied to Emergence of Chemotherapy Resistance

Researchers say analyzing a particular gene in high-grade serous cancer (HGSC) could help predict whether a patient’s tumor is likely to become resistant to chemotherapy over time. A team headed by researchers at the Peter MacCallum Cancer Center in Melbourne, Australia, has found that the emergence of treatment resistance in HGSC is associated with a loss or downregulation of the lipid transporter LRPB1 in the tumor. ...
Page 4 of 34« First...23456...102030...Last »